Collagen for Joint Health: Types, Doses, and What the Trials Show

The word "collagen" on a supplement label communicates almost nothing useful. It does not tell you whether the ingredient is hydrolyzed or native, whether it targets substrate supply or immune modulation, whether the effective dose is 40 milligrams or 10 grams, or whether the clinical evidence behind it comes from a 191-patient multicenter trial or a marketing whitepaper.

This matters because the supplement industry now sells collagen in capsules, powders, gummies, beverages, bars, and topical creams. The global collagen supplement market was valued at approximately $7.2 billion in 2024 and is projected to reach $12 billion by 2030. Growth that fast attracts undifferentiated products, and undifferentiated products produce undifferentiated results.

For formulators, purchasing teams, and anyone evaluating collagen ingredients for joint health, the starting point is understanding that "collagen" refers to at least two genuinely different categories of ingredient. They share a name. They share almost nothing else.

Types I, II, and III: What They Are and Where They Come From

The human body contains at least 28 types of collagen, but three account for the vast majority of structural protein in connective tissue.

Type I collagen is the most abundant protein in the human body. It is the primary structural component of skin, tendons, ligaments, bone, and the cornea. Roughly 90% of the collagen in your body is Type I. Commercially, it is sourced from bovine hides, fish skin (primarily tilapia and cod), and, increasingly, from bovine bone and porcine skin. It is the backbone of the "beauty collagen" category and the dominant type in hydrolyzed collagen peptide products.

Type II collagen is found almost exclusively in articular cartilage — the smooth, glassy tissue that caps the ends of bones at every joint. It forms a fibrillar network that gives cartilage its tensile strength and resilience. Commercially, Type II collagen is sourced from chicken sternum cartilage (the standard for undenatured type II products) and from bovine or porcine cartilage. The critical distinction is whether the extraction process preserves or destroys the native triple-helix structure.

Type III collagen co-localizes with Type I in skin, blood vessels, and internal organs. It is the second most abundant collagen in the body and plays a role in tissue elasticity and wound healing. It is present in bovine and porcine collagen extracts but is not typically sold as a standalone ingredient for joint health.

Hydrolyzed Collagen Peptides: Substrate Supply at 5–10 Grams

Hydrolyzed collagen — also called collagen peptides or collagen hydrolysate — is collagen protein that has been enzymatically broken into short peptide chains, typically 2–5 kilodaltons in molecular weight. The native triple-helix structure is destroyed. What remains are small, highly bioavailable peptide fragments rich in glycine (approximately 33% of amino acid content), proline (12–14%), and hydroxyproline (10–12%).

The mechanism is substrate supply. Collagen peptides deliver the amino acids and di/tripeptides that the body uses as raw material for its own collagen synthesis. Hydroxyproline-containing peptides (Pro-Hyp and Hyp-Gly, specifically) have been detected in human blood after oral ingestion, suggesting they survive digestion and reach target tissues intact. A 2005 pharmacokinetic study by Iwai et al. detected food-derived hydroxyproline-containing peptides in human blood at peak concentrations 1–2 hours after oral intake of 10 grams of collagen hydrolysate.

The clinical doses are 5–10 grams per day. An updated 2024 meta-analysis of 35 randomized controlled trials pooling 3,165 patients found that collagen peptide supplementation produced small-to-moderate improvements in joint pain and function compared with placebo, with a safety profile comparable to placebo. A separate 2023 meta-analysis of four trials in 507 knee osteoarthritis patients reached similar conclusions.

The sourcing for hydrolyzed collagen peptides varies. Bovine hide collagen is the most common and cheapest — the raw material is a byproduct of the leather industry. Marine collagen from fish skin commands a 20–40% premium and carries a clean-label appeal for consumers avoiding mammalian ingredients. Chicken collagen from sternal cartilage is less common in the hydrolyzed format but is used when Type II-enriched peptides are desired.

Undenatured Type II Collagen: Immune Modulation at 40 Milligrams

Undenatured type II collagen (UC-II) is a completely different ingredient that works through a completely different biological pathway. The collagen is extracted from chicken sternum cartilage under low-temperature conditions that preserve the native triple-helix structure, the intact polypeptide chains, and the immunologically active epitopes.

The mechanism is oral tolerance, mediated by gut-associated lymphoid tissue. When small amounts of native type II collagen reach the Peyer’s patches in the small intestine, they interact with T-regulatory cells in a way that downregulates the autoimmune-like inflammatory response that contributes to cartilage degradation in osteoarthritis. This is not speculation — oral tolerance is a well-characterized immunological phenomenon that has been studied in rheumatoid arthritis since the 1990s. The application to osteoarthritis is newer but supported by clinical data.

The defining trial is the 2016 multicenter randomized controlled study by Lugo et al. published in the International Journal of Medical Sciences. It enrolled 191 patients with knee osteoarthritis and randomized them to 40 mg of UC-II daily, 1,500 mg glucosamine + 1,200 mg chondroitin daily, or placebo, for 180 days. UC-II produced statistically significant and clinically meaningful improvements in WOMAC pain, stiffness, and function scores — greater than both the glucosamine/chondroitin combination and placebo. A 2024 meta-analysis in the Journal of Translational Research reviewed the accumulated evidence and concluded that UC-II at 40 mg daily is safe and effective for reducing pain and improving joint function.

HS Biopharma’s Native CT-II® is a UC-II-style ingredient: undenatured type II collagen from chicken sternum cartilage, manufactured under a proprietary process that preserves the native triple-helical structure and active epitopes required for the oral-tolerance mechanism. The effective dose is 40 mg daily — roughly 1/250th the weight of a standard collagen peptide serving. That dose differential is not a marketing trick. It reflects the fundamentally different mechanism: you are not feeding the body raw material, you are modulating an immune response.

A 40 mg daily dose of undenatured type II collagen outperformed a 1,500 mg glucosamine + 1,200 mg chondroitin regimen in a 180-day multicenter trial. The mechanism is not nutritional. It is immunological.

The Vegan Question: Plant-Based Collagen Alternatives

Collagen is, by definition, an animal protein. Plants do not produce collagen. This creates a real gap for the growing segment of vegan and vegetarian consumers interested in joint and skin health.

The workarounds fall into two categories. The first is collagen-boosting formulas: combinations of vitamin C, proline, glycine, copper, and silica that provide the precursors and cofactors for endogenous collagen synthesis. These are nutritionally logical but have limited direct clinical evidence for joint outcomes.

The second is collagen-mimetic peptides — plant-derived protein hydrolysates engineered to approximate the amino acid profile of human collagen. HS Biopharma’s Kollaveg™ falls in this category: a plant-based peptide with reported >95% amino acid similarity to human Type I collagen, a molecular weight of approximately 500 Da (far smaller than animal-derived hydrolyzed collagen at 2,000–5,000 Da), and hydroxyproline content of at least 9%. The low molecular weight enables fast absorption, and the hydroxyproline content addresses the key limitation of most plant proteins — they contain essentially zero hydroxyproline, the amino acid that defines collagen’s structural stability.

Kollaveg™ is dosed at 2.5–5 grams daily, consistent with the substrate-supply mechanism of hydrolyzed collagen rather than the oral-tolerance mechanism of UC-II. It does not replace native type II collagen for immune-mediated joint support. It fills a different gap: providing the collagen amino acid profile to consumers who will not use animal-derived ingredients.

Sourcing: Marine vs. Bovine vs. Chicken

The animal source of collagen is not a preference question — it determines the collagen type composition, which determines the appropriate application.

Marine collagen from fish skin is almost exclusively Type I. It has a lower hydroxyproline content than mammalian collagen (approximately 8–10% vs. 12–14%) due to the lower body temperature of fish, which affects the thermal stability of the triple helix. Fish collagen peptides also have slightly lower gelling temperatures, which can be advantageous in beverage applications. The premium over bovine collagen reflects sourcing complexity and consumer perception rather than demonstrated clinical superiority for joint outcomes.

Bovine collagen from hides is predominantly Type I with meaningful Type III content. It is the workhorse of the hydrolyzed collagen market — highest volume, lowest cost, broadest clinical evidence base. Bovine bone collagen also exists but is less common in the supplement space.

Chicken collagen from sternum cartilage is the primary source for Type II collagen, both hydrolyzed and undenatured. For the oral-tolerance mechanism specifically, chicken sternum is the standard. All major UC-II trials, including the Lugo 2016 trial, used chicken-sternum-derived material.

What to Actually Do With This

The practical logic for collagen in joint-health formulations is straightforward once you separate the two mechanisms.

If the target consumer has established osteoarthritis pain and you want a clinically differentiated low-dose ingredient, undenatured type II collagen at 40 mg daily has the strongest single-trial evidence (the Lugo 2016 multicenter study) and a distinctive mechanism. HS Biopharma’s Native CT-II® is built for this application. The small dose enables single-capsule delivery and easy stacking with other joint ingredients.

If the target consumer is an active adult looking for general joint and connective-tissue support, hydrolyzed collagen peptides at 5–10 grams daily have a broader (though individually weaker) evidence base from 35+ trials. Choose the source based on market positioning: marine for premium clean-label, bovine for cost efficiency, chicken for Type II-enriched peptide profiles.

If the target consumer is vegan, the only credible option is a collagen-mimetic plant peptide. Kollaveg™’s amino acid profile is the closest analog to animal collagen currently available in the plant-based space. Dose at 2.5–5 grams daily.

Do not mix up the mechanisms. A 40 mg dose of hydrolyzed collagen will do nothing — it is a trivial amount of protein. A 10-gram dose of native undenatured type II collagen will waste money and may not trigger the oral-tolerance mechanism, which depends on controlled low-dose exposure. Match the collagen type to the mechanism you are targeting, and dose accordingly. Everything else is marketing.